GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)

Trial Profile

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Antithrombotics (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 26 Sep 2017 Results (n=2932) of part 2 assessing the predictors of dabigatran etexilate persistence over 2 years of follow-up in patients with newly diagnosed atrial fibrillation, published in the Journal of the American College of Cardiology.
    • 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Feb 2017 Results of phase II part of this study (n=15092) published in the Journal of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top